Interestingly, acute lymphoblastic leukemia (ALL) blasts that were nonresponsive to BiTE therapy had higher surface PD-L1 expression, and blocking of CD80 signaling in preclinical ALL models led to decreased efficacy (49). Here, CD80 is linked to acute lymphoblastic leukemia.